Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

Paolo Zocca, Liefke C. van der Heijden, Marlies M. Kok, Marije M. Löwik, Marc Hartmann, Martin G. Stoel, Johannes W. Louwerenburg, Frits H.A.F. de Man, Gerard C.M. Linssen, Iris L. Knottnerus, Carine J.M. Doggen, Gert K. van Houwelingen, Clemens von Birgelen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)
163 Downloads (Pure)

Abstract

Aims: Acute coronary syndrome (ACS) guidelines have been changed, favouring more potent antiplatelet drugs. We aimed to evaluate the safety and efficacy of a ticagrelor- instead of a clopidogrel-based primary dual antiplatelet (DAPT) regimen in ACS patients treated with newer-generation drug-eluting stents (DES).

Methods and results: CHANGE DAPT (clinicaltrials.gov: NCT03197298) assessed 2, 062 consecutive real-world ACS patients, treated by percutaneous coronary intervention (PCI), the primary composite endpoint being net adverse clinical and cerebral events (NACCE: all-cause death, any myocardial infarction, stroke or major bleeding). In the clopidogrel (CP; December 2012-April 2014) and ticagrelor periods (TP; May 2014-August 2015), 1, 009 and 1, 053 patients were treated, respectively. TP patients were somewhat older, underwent fewer transfemoral procedures, and received fewer glycoprotein IIb/IIIa inhibitors. In the TP, the one-year NACCE rate was higher (5.1% vs. 7.8%; HR 1.53 [95% CI: 1.08-2.17]; p=0.02). Assessment of non-inferiority (pre-specified margin: 2.7%) was inconclusive (risk difference: 2.64 [95% CI: 0.52-4.77]; pnon-inferiority=0.48). TP patients had more major bleeding (1.2% vs. 2.7%; p=0.02) while there was no benefit in ischaemic endpoints. Propensity score-adjusted multivariate analysis confirmed higher NACCE (adj. HR 1.75 [95% CI: 1.20-2.55]; p=0.003) and major bleeding risks during TP (adj. HR 2.75 [95% CI: 1.34-5.61]; p=0.01).

Conclusions: In this observational study, the guideline-recommended ticagrelor-based primary DAPT regimen was associated with an increased event risk in consecutive ACS patients treated with newer-generation DES.

Original languageEnglish
Pages (from-to)1168-1176
Number of pages9
JournalEuroIntervention
Volume13
Issue number10
DOIs
Publication statusPublished - 1 Nov 2017

Keywords

  • Acute coronary syndrome
  • Adjunctive pharmacotherapy
  • Drug-eluting stent
  • Non-ST-elevation acute coronary syndrome
  • ST-elevation myocardial infarction

Fingerprint Dive into the research topics of 'Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT'. Together they form a unique fingerprint.

  • Cite this

    Zocca, P., van der Heijden, L. C., Kok, M. M., Löwik, M. M., Hartmann, M., Stoel, M. G., ... von Birgelen, C. (2017). Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention, 13(10), 1168-1176. https://doi.org/10.4244/EIJ-D-17-00634